of endothelial function and arterial stiffness, such as brachial artery flow-mediated dilation (FMD), fingertip peripheral arterial tonometry (PAT), and arterial tonometry, are associated with cardiovascular risk factors and with incident CVD. [16] [17] [18] [19] [20] There have been several studies on the association of NAFLD and various markers of vascular structure and function. [21] [22] [23] [24] [25] [26] [27] [28] [29] [30] [31] [32] [33] These studies have been limited by small sample sizes, lack of adequate control for known cardiovascular risk factors, limited evaluation of vascular function, and use of clinical samples. [22] [23] [24] [25] [26] [27] [28] [29] [30] [31] [32] [33] Thus, the goal of our study was to determine the association between NAFLD, as defined by decreased liver attenuation on multidetector computed tomography (CT), and vascular function, as measured by brachial artery FMD, PAT, and arterial tonometry in a large, unselected community-based cohort without apparent CVD. In addition, we explored whether associations remained after adjusting for known cardiovascular risk factors, body mass index (BMI), and visceral adipose tissue.
Materials and Methods
Materials and Methods are available in the online-only Data Supplement.
Results

Study Sample Characteristics
Participant characteristics and mean values for vascular function measures for those with and without NAFLD are summarized in Table 1 . Overall, 15 .3% of the sample had a liver phantom ratio (LPR) of ≤0.33, consistent with NAFLD.
Correlations Between Liver Attenuation and Vascular Function Measures
In minimally adjusted models, liver attenuation was significantly correlated with all vascular function measures, except for hyperemic mean flow velocity and forward-wave amplitude (Table 2) . With more liver fat (lower LPR), the response to ischemia as measured by FMD was lower, which is consistent with conduit vessel dysfunction. More liver fat was also associated with a lower PAT ratio, which is consistent with small vessel dysfunction. For the measures of arterial stiffness, more liver fat was associated with a higher carotidfemoral pulse wave velocity, which is consistent with greater arterial stiffness.
Multivariable-Adjusted Partial Correlations for NAFLD With Vascular Function Measures
In the multivariable-adjusted model, NAFLD (LPR≤0.33) was positively associated with mean arterial pressure (r=0.06; P=0.005) and inversely associated with the PAT ratio (r=−0.12; P<0.0001; Table 3 ). After BMI was added to the multivariable model, the correlation between NAFLD (LPR≤0.33) and mean arterial pressure was no longer statistically significant (r=0.03, P=0.20). NAFLD (LPR≤0.33) was also positively associated with carotid-femoral pulse wave velocity in the multivariable-adjusted model (r=0.05; P=0.03); however, when this model was also adjusted for mean arterial pressure, the correlation was no longer statistically significant (r=0.02; P=0.29). The correlation between NAFLD (LPR≤0.33) and the PAT ratio remained statistically significant after additionally adjusting for BMI (r=−0.09; P=0.0005) and visceral adipose tissue (r=−0.08; P=0.004; Table 3 ). NAFLD (LPR≤0.33) also was associated with higher baseline brachial artery diameter (multivariable model 1 only), baseline brachial artery mean flow velocity, and baseline peripheral artery pulse amplitude (Table II in the online-only Data Supplement). When we evaluated LPR as a continuous variable, results were largely similar ( Table 3) . The variance inflation factor was <1.3 for each of these associations, suggesting the lack of severe multicollinearity.
PAT Ratio According to the Presence of NAFLD Overall and Across BMI Categories
The least-square means for the PAT ratio according to the presence of NAFLD overall and by BMI category are shown in Figure. Overall, the PAT ratio was lower among participants with NAFLD compared with those without NAFLD (P<0.0001). In the overweight BMI category, the PAT ratio in participants with NAFLD was lower compared with those without NAFLD (P=0.0006), which is consistent with small vessel dysfunction. In the normal weight and obese BMI categories, the findings are in a similar direction; however, not statistically significant (PAT ratio normal weight NAFLD versus non-NAFLD, P=0.26; PAT ratio obese NAFLD versus non-NAFLD, P=0.06).
PAT Ratio According to the Presence of NAFLD and CRP Above and Below Median
The least-square means for the PAT ratio according to the presence of NAFLD and CRP above and below the median value are shown in Figure I in the online-only Data Supplement. Participants with NAFLD and either CRP<median or CRP≥median had a significantly lower PAT ratio compared with those without NAFLD and CRP < median (P=0.008 and P<0.0001, respectively). Among those with NAFLD, there was no difference in the PAT ratio in those with CRP>median versus CRP≤median (P=0.99).
PAT Ratio According to the Presence of NAFLD and Normal or Elevated Liver Function Tests
The lease-square means for the PAT ratio according to the presence of NAFLD and elevated liver function tests (LFTs) Continuous variables expressed as mean±SD and categorical variables as n (%) unless noted. LPR indicates liver phantom ratio; and NAFLD, nonalcoholic fatty liver disease.
*Clinical characteristics were assessed for the offspring participants at examination 7. Adiposity measures were assessed for the offspring participants between examinations 7 and 8. Peripheral arterial tonometry and arterial tonometry variables were assessed for the offspring participants at examination 8. Third-generation participants had clinical characteristics and all vascular function measurements assessed at examination 1.
†Values represent median (interquartile range). ‡Peripheral artery tone measures are natural logarithm transformed.
Sex Interactions
In multivariable models of the main outcome measures, there was no evidence of effect modification by sex (P value range, 0.16-0.90).
Analysis Limited to the Third-Generation Cohort
In a secondary analysis limited to participants in the ThirdGeneration Cohort who had all vascular function measurements and the multidetector CT scans at the same study visit, the results were not substantively changed (Table III in 
Analysis Limited to the Participants With All 3 Vascular Measures
In a secondary analysis limited to participants who had all 3 vascular measures (n=1005), the results were not substantively changed (Table IV in the online-only Data Supplement).
Discussion
In this large (n=2284) community-based cohort of participants without apparent CVD, we observed modest associations between lower liver attenuation (more liver fat) and FMD, a measure of conduit artery vasodilator function; PAT ratio, a measure of microvascular function; mean arterial pressure, a measure of systemic perfusion; and carotid-femoral pulse wave velocity, a measure of arterial stiffness. The associations of NAFLD with conduit artery function and arterial stiffness were attenuated and no longer significant after adjusting for CVD risk factors. However, NAFLD remained correlated with measures of microvascular dysfunction, including PAT ratio, baseline brachial artery mean flow velocity, and baseline peripheral artery pulse amplitude even in models adjusted for CVD risk factors and adiposity measures. These findings are consistent with a potential association between NAFLD and microvascular dysfunction. We advance the previous literature by evaluating microvascular dysfunction in NAFLD as measured by PAT. Although both are markers of vasodilator function, brachial and digital measures of vasodilation evaluate distinct vascular beds and previous work suggests they reflect distinct aspects of vascular function. [34] [35] [36] We have previously demonstrated differences in the risk factors associated with brachial hyperemia and PAT with low digital vascular function being associated with metabolic risk factors, including BMI, cholesterol, and the presence of diabetes mellitus. 34, 37 Relevant to NAFLD, one previous selected study of patients with obstructive sleep apnea identified an association between hepatic steatosis and lower PAT. 38 The present investigation demonstrates, in a large community-based sample, an association between PAT ratio and NAFLD after adjusting for cardiovascular and metabolic risk factors. Furthermore, across categories of obesity, the presence of NAFLD was associated with lower PAT hyperemic response. High baseline brachial flow is also gaining appreciation as a metabolic disease-associated vascular alteration. 39 In this study, we observed higher resting flow velocity in participants with NAFLD that may contribute to microvascular damage. These results emphasize the association of NAFLD with abnormalities in the microcirculation.
Previous smaller studies have evaluated the relationship of NAFLD with several individual measures of vascular function. In small, clinically selected samples, patients with biopsyproven NAFLD had conduit artery dysfunction, as measured by brachial artery FMD, compared with age-and sex-matched controls. 24, 26 The association of clinical NAFLD with reduced FMD persisted when accounting for a limited set of metabolic risk factors. 24, 28 NAFLD determined by ultrasound also has been associated with lower endothelium-dependent dilation in clinical samples. 22, 25, 31 Similarly, one study showed higher aortic stiffness in patients with biopsy-proven NAFLD. 28 In community-based cohorts, an association was observed between sonographically defined NAFLD and higher arterial stiffness measured using global stiffness measures, brachial-ankle pulse wave velocity, and carotid-femoral pulse wave velocity. 28, 29, 32 However, in a study of adolescents with ultrasound-defined NAFLD, the association between NAFLD and higher arterial stiffness was limited to participants with high-risk metabolic features, including greater waist circumference, triglycerides, insulin, systolic blood pressure, and lower high-density lipoprotein. 27 Thus, whether NAFLD is associated with abnormal vascular function beyond the associated cardiometabolic risk factors remained unclear.
In this study, we had the opportunity to evaluate multiple measures reflecting distinct aspects of vascular health in a community-based sample with a comprehensive assessment of cardiometabolic risk factors. In contrast to previous work, we observed that the NAFLD was no longer associated with conduit artery function or aortic stiffness after adjusting for concurrent risk factors. Thus, our findings suggest that the risk factors that cluster with NAFLD account for the observed vascular dysfunction, particularly in the conduit and large arteries. There are several possible explanations for these apparently discrepant results. First of all, several of the previous studies used hospital-based patient samples, which may have a higher prevalence of comorbid conditions that contribute to conduit artery dysfunction and arterial stiffness compared with our study in a community-based sample. It is also possible that large artery dysfunction and arterial stiffness occur later in the pathogenesis of NAFLD. In addition, the large sample size and detailed assessment of cardiovascular risk factors, including adiposity measures, allowed for a more complete adjustment for potential confounding in our study. Thus, NAFLD may be associated with vascular dysfunction through processes that also drive the occurrence of traditional risk factors, including dyslipidemia, hyperglycemia, insulin resistance, and blood pressure. Several potential factors may underlie the association of NAFLD with vascular dysfunction. Liver fat accumulation occurs in a complex of metabolic disturbances, including abdominal obesity and dyslipidemia. 4 Thus, isolating the association of fatty liver from the coexistent metabolic disruptions is not straightforward. Endothelial dysfunction may also contribute to the development of fatty liver. 33 It has been proposed that the liver is both exposed to an abnormal metabolic environment and a source of substances that promote vascular damage. 13 Fatty liver has been associated with increased proinflammatory cytokine production and heightened oxidative stress. 13 Thus, reduced vascular function associated with NAFLD may reflect systemic inflammation. Both conduit and small vessel FMD depend on endothelial production of nitric oxide that may be reduced in the setting of inflammation. 40 However, it may be that small vessel vasodilator responses have greater susceptibility to metabolic insults, including NAFLD, before the development of atherosclerotic disease. 17, 34 Further longitudinal studies are needed to define the precise mechanisms linking NAFLD to microvascular damage.
The major strengths of our investigation include our use of a large community-based sample that has not been selected for NAFLD and the detailed assessment of multiple measures of vascular function. In this well-characterized sample with a thorough assessment of covariates using standardized measurements, we are able to add to the present literature by adjusting for several important confounders in exploring the association with endothelial dysfunction and NAFLD in multivariable models.
There are several important limitations to our investigation that warrant mention. First, the cross-sectional design of this observational study precludes any inferences on causality or *Multivariable models adjusted for age, sex, cohort, smoking, mean arterial pressure (not included in models with mean arterial pressure or CFPWV as dependent variable, unless noted), heart rate, walk test (before, only for brachial measures †), total/high-density lipoprotein cholesterol, triglycerides, fasting glucose level, menopause, hormone replacement therapy, diabetes mellitus, hypertension treatment, and lipid-lowering treatment.
‡Not adjusted on mean arterial pressure. §Additionally adjusted on carotid femoral pulse wave velocity.
temporality. The Framingham Heart Study is largely white; so, results may not be generalizable to individuals of nonEuropean ancestry. In addition, we defined NAFLD based on CT imaging, which likely under-represents the burden of NAFLD in the population, which may have led to nondifferential misclassification biasing our results to the null. 41 Also, CT imaging cannot accurately detect steatohepatitis; so, we are unable to determine the association of vascular function and NAFLD disease severity. We also lack information about viral hepatitis status and other chronic liver conditions, which can cause the appearance of liver fat on CT scan. However, these findings would likely lead to misclassification and would bias our findings toward the null. Thus, they are unlikely to account for our positive results. For the Offspring Cohort participants, there were temporal differences between the vascular measures and CT scans. However, in a sensitivity analysis limited to the ThirdGeneration Cohort participants who had vascular measures and CT scans at the same study visit, our results were similar. In addition, those participants with available PAT measurements were older and had more cardiometabolic risk factors compared with those with missing data. This may have led to a selection bias away from the null. However, when the analysis was repeated in participants who had all vascular measures, the results were largely unchanged. Overall, although statistically significant, the magnitude of the association between NAFLD and the PAT ratio is modest. Future longitudinal studies are necessary to explore the clinical significance of our findings.
We observed an association between NAFLD and markers of endothelial dysfunction and arterial stiffness. Future longitudinal studies are required to further explore the association between NAFLD and microvascular dysfunction and how this relates to cardiovascular risk.
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